The Efficacy and Safety of Antiinterleukin 13, a Monoclonal Antibody, in Adult Patients with Asthma

Medicine (United States)

Volumn 95, Issue 6, 2016, Pages

  Luo, Jian ^a   Liu, Dan ^a   Liu, Chun Tao ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANRUKINZUMAB; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; INTERLEUKIN 13 ANTIBODY; LEBRIKIZUMAB; METHACHOLINE; NITRIC OXIDE; TRALOKINUMAB; ANTIASTHMATIC AGENT; INTERLEUKIN 13; MONOCLONAL ANTIBODY;

ADULT DISEASE; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL COUNT; FORCED EXPIRATORY VOLUME; FRACTION OF EXHALED NITRIC OXIDE; HUMAN; LUNG FUNCTION; META ANALYSIS; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT PARAMETERS; SYSTEMATIC REVIEW; ADULT; IMMUNOLOGY; STATISTICAL MODEL; TREATMENT OUTCOME;

ADULT; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; HUMANS; INTERLEUKIN-13; MODELS, STATISTICAL; TREATMENT OUTCOME;

EID: 84958259733     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002556     Document Type: Article

References (23)

1. Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA), 2012. Available at www.ginasthma.org
2. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest. 2003;111: 1863-1874
3. Yang M, Rangasamy D, Matthaei KI, et al. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J Immunol. 2006;177:5595-5603
4. Gray MJ, Poljakovic M, Kepka-Lenhart D, et al. Induction of arginase I transcription by IL-4 requires a composite DNA response element for STAT6 and C/EBPbeta. Gene. 2005;353: 98-106
5. Hobbs CA, Gilmour SK. High levels of intracellular polyamines promote histone acetyltransferase activity resulting in chromatin hyperacetylation. J Cell Biochem. 2000;77:345-360
6. Ricciardolo FL, Zaagsma J, Meurs H. The therapeutic potential of drugs targeting the arginase pathway in asthma. Expert Opin Investig Drugs. 2005;14:1221-1231
7. Howell JE, Mcanulty RJ. TGF-beta: its role in asthma and therapeutic potential. Curr Drug Targets. 2006;7:547-565
8. de Boer J, Meurs H, Flendrig L, et al. Role of nitric oxide and superoxide in allergen-induced airway hyperreactivity after the late asthmatic reaction in guinea-pigs. Br J Pharmacol. 2001;133:1235-1242
9. Maarsingh H, Bossenga BE, Bos IS, et al. L-Arginine deficiency causes airway hyperresponsiveness after the late asthmatic reaction. Eur Respir J. 2009;34:191-199
10. Singh D, Kane B, Molfino NA, et al. A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma. BMC Pulm Med. 2010;10:1-8
11. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011;365:1088-1098
12. LaPorte SL, Juo ZS, Vaclavikova J, et al. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system. Cell. 2008;132:259-272
13. Hodsman P, Ashman C, Cahn A, et al. A phase 1, randomized, placebocontrolled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics. Br J Clin Pharmacol. 2013;75:118-128
14. Higgins JP, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [Updated March 2011]. Oxford: The Cochrane Collaboration; 2011. Available at: www.co chrane-handbook.org. Accessed 20 March 2011
15. Gauvreau GM, Boulet LP, Cockcroft DW, et al. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011;183:1007-1014
16. Noonan M, Korenblat P, Mosesova S, et al. Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids. J Allergy Clin Immunol. 2013;132:567.e12-574.e12
17. Piper E, Brightling C, Niven R, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J. 2013;41:330-338
18. De Boever EH, Ashman C, Cahn AP, et al. Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. J Allergy Clin Immunol. 2014;133:989-996
19. Scheerens H, Arron JR, Zheng Y, et al. The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge. Clin Exp Allergy. 2014;44:38-46
20. Dweik RA, Boggs PB, Erzurum SC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184:602-615
21. Maarsingh H, Pera T, Meurs H. Arginase and pulmonary diseases. Naunyn Schmiedebergs Arch Pharmacol. 2008;378:171-184
22. Juniper EF, OByrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14:902-907
23. Masoli M, Fabian D, Holt S, et al. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59:469-478